CPH — Cipher Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- CA$204.91m
- CA$150.63m
- $21.16m
- 97
- 72
- 100
- 99
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22.5 | 21.6 | 21.9 | 20.7 | 21.2 |
Cost of Revenue | |||||
Gross Profit | 19.5 | 18.6 | 18.3 | 16.7 | 17.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 15.9 | 14.9 | 10.1 | 9.63 | 11.1 |
Operating Profit | 6.59 | 6.74 | 11.8 | 11.1 | 10 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 5.71 | 6.54 | 11.1 | 11.5 | 12.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.64 | 4.39 | 7.76 | 26.6 | 20.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 3.24 | 4.55 | 7.76 | 26.6 | 20.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3.24 | 4.55 | 7.76 | 26.6 | 20.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.198 | 0.293 | 0.342 | 1.03 | 0.802 |